RT Journal
A1 Mitka M
T1 NEw hiv drug pricing
JF JAMA
JO JAMA
YR 2012
FD October 10
VO 308
IS 14
SP 1421
OP 1421
DO 10.1001/jama.2012.13452
UL http://dx.doi.org/10.1001/jama.2012.13452
AB 
In an August 1 letter to Gilead Sciences, the representatives said setting a wholesale price above $27 000 annually for the tablet would cause problems for the AIDS Drug Assistance Program (ADAP), the federally funded program that helps states purchase HIV/AIDS drugs for low-income individuals who have limited or no prescription drug coverage. ADAP is funded through the Ryan White Program.